Cytogenix (fka CYGX)

[neo43]

CYGX believes it has enough money . . .

to last it through Q1, per Juan Ferreira, the company's IR representative.

Assuming the IND application for the Herpes treatment is made by then, the SP will probably put the company in a stronger position to raise the necessary funds to carry on.

Unless we have substantial news, I really doubt we'll see a lot of upside movement before then. However, I also don't believe we'll see significantly lower prices -- unless emotions take over and people panic-sell. The most likely scenario IMHO is that the SP will trade pretty much sideways in the absence of news.